Medical Director Early Clinical Development


  • Medical Doctor and PhD at University of Copenhagen
  • License to practice independent medicine
  • Specialist in medical oncology and radiotherapy


16 years of Clinical experience, 6 years of basic research and 14 years of drug development.


Key areas of interest include

  • Early clinical development phase I trials
  • Proof of concept trials - randomized phase II trial
  • Development of strategic plans, target product profile, interactions with health authorities

Experience and publications

Title

Authors

Journal

Link to publication

Retroperitoneal Fibrosis after Long-term Daily Use of Ergotamine

Damstrup L. and Jensen T.T.

Int U Nephr 1986, 18, 299-301

Effects of Antineoplastic Treatment of HIV-positive Patients with Testicular Cancer

Damstrup L., Daugaard G., Gerstoft J. and Rørth M.

Eur J Can Clin Oncol 1989, 25, 983-986

Growth Factors in Human Malignancies with Special Reference to Lung Cancer: A Review

Damstrup L., Rørth M. and Skovgaard Poulsen H.

Lung Cancer 1989, 5, 49-68

Immunocytochemical Assay for the Estrogen-regulated Proteins Mr 52,000 and Mr 24,000 in Primary Breast Cancer correlation with Estrogen Receptor and Response to Endocrine Therapy

Damstrup L., Andersen J. and Skovgaard Poulsen H.

Life Sci Adv. 1990, 9, 69-76

N/A

Estrogen-regulated Proteins in Human Breast Cancer: Relation to Clinical Parameters. In: Recent Advances in Cellular and Molecular Biology

Damstrup L., Andersen J., Hayes D.F. and Skovgaard Poulsen H.

Wegmann R.J. & Wegmann M.A. (eds). Peeters Press, Leuven, 1992, 4, 243-251

N/A - Book Chapter

Immunocytochemical Determination of the Estrogen-regulated Proteins Mr 52,000, Mr 24,000 and DF3 Breast Cancer Associated Antigen: Clinical Value in Advanced Breast Cancer and Correlation with Estrogen Receptor

Damstrup L., Andersen J., Kufe D.W., Hayes D.F. and Skovgaard Poulsen H.

Ann. Oncol. 1992, 3, 71-77

Expression of Epidermal Growth Factor Receptors in Small Cell Lung Cancer Cell Lines

Damstrup L., Rygaard K., Spang Thomsen M., Skovgaard Poulsen H.

Cancer Res. 1992, 52, 3089-3093

Transforming Growth Factor-β. A Multipotent Growth Factor for Normal and Malignant cells

Nørgaard P., Damstrup L., Spang-Thomsen M. and Skovgaard Poulsen H.

Ugeskrift for laeger 1992, 154, 3494-3498

Expression of the Transforming Growth Factor β (TGFβ) Receptors and TGFβ1, TGFβ2 and TGFβ3 in Small Cell Lung Cancer Cell Lines

Damstrup L., Rygaard K., Spang Thomsen M., Skovgaard Poulsen H.

Br. J. Cancer 1993, 67, 1015-1021

Receptors for the growth factors TGFα and TGFβ in human small cell lung cancer

Damstrup L.

PhD thesis, Copenhagen 1993 Abstract printed in Danish Medical Bulletin 1994, 41, 93

N/A

Growth Suppresion by Transforming Growth Factor β1 of Human Small Cell Lung Cancer Cell Lines is Associated to Expression of the type II Receptor

Nørgaard P., Damstrup L., Rygaard K., Spang Thomsen M., Skovgaard Poulsen H.

Br. J. Cancer, 1994, 69, 802-808

Review of the Curative Role of Radiotherapy in the Treatment of Non-Small Cell Lung Cancer

Damstrup L. and Skovgaard Poulsen H.

Lung Cancer, 1994, 11, 153-178

Auto- and Cross-induction within the Mammalian Epidermal Growth Factor-related Peptide Family

Barnard J., Graves-Deal R., Pittelkow MR., DuBois R., Cook P., Ramsey GW., Bishop PR., Damstrup L. and Coffey RJ.

J. Bio. Chem, 1994, 269, 22817-22822

Basic Actions of TGFα and Related Peptides

Coffey R., Gangarosa L., Damstrup L and Dempsey P J.

Eur. J. Cancer. 1996

Acquired TGFβ sensitivity and TGFβ1 expression in cell lines established from a single small cell lung cancer patient during clinical progression

Nørgaard P., Damstrup L., Rygaard K., Spang Thomsen M., Skovgaard Poulsen H.

Lung Cancer, 1996, 14, 63-73

Transforming growth factor-α

Gangarosa L., Dempsey P J., Damstrup L. and Coffey R J.

Clin. Gastroenterol., 1996, 10, 49-63

Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells

Coffey RJ, Hawkey C., Damstrup L., Graves-Deal R., Daniel VC., Dempsey PJ., Chinery R., Kirkland S., DuBois RN., Jetton TL. and Morrow JD.

PNAS, 1997, 94, 657-662

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

Voldborg, B., Damstrup L., Spang-Thompsen and Skovgaard Poulsen H.

Annals of Oncology, 1997, 8, 1197-1206

In vitro invasion of small cell lung cancer cell lines correlation to the epidermal growth factor receptor

Damstrup L., Voldborg, B.R., Spang-Thomsen M., Brünner N., Skovgaard Poulsen H.

Br. J Cancer 1998, 78, 631-640

High value of the radiobiological parameter Dq correlates to the expression of transforming growth factor β type II receptor in a panel of human small cell lung cancer cell lines

Hougaard S., Krarup M., Nørgaard P., Damstrup L., Spang-Thomsen M. and Skovgaard Poulsen H.

Lung Cancer, 1998, 20, 65-69

Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer cell lines that exhibit domain selective EGF receptor mitogenesis

Damstrup L., Kuwada SK., Dempsey PJ., Brown CL., Hawkey CJ., Skovgaard Poulsen H., Wiley HS. and Coffey RJ.

Br. J. Cancer 1999, 80, 1012-1019

The dynamic expression of the epidermal growth factor receptor and epidermal growth factor ligand family in a differentiated intestinal epithelial cell line

Kuwada SK., Li X-F., Damstrup L., Dempsey PJ., Coffey RJ. and Wiley HS.

Growth factors 1999, 17, 139-153

Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor

Stensgaard Frederiksen K., Abrahamsen N., Christiano RJ., Damstrup L., and Skovgaard Poulsen H.

Cancer Gene Therapy 2000, 7, 262-8

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

Petersen MW., Meltorn M., Damstrup L and Skovgaard Poulsen H.

Ann Oncology 2001, 12, 745-60

Profile of differentially expressed genes mediated by the type III epidermal growth factor receptor mutation in a small-cell lung cancer cell line

Petersen MW., Thykjær T., Ørntoft TF., Damstrup L and Skovgaard Poulsen H.

Br. J. Cancer, 2001, 85, 1211-1218

Epidermal growth factor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhance the malignant phenotype

Damstrup L., Petersen MW., Bastholm L., Elling F. and Skovgaard Poulsen.

International Journal of Cancer, 2002, 97, 7-14

Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation

Petersen MW., Petersen N., Damstrup L., Villingshoj M., Sonder SU., Rieneck K., Bovin LF., Spang-Thomsen M. and Skovgaard Poulsen H.

J. Cell Biochem, 2005, 96, 412-27

Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies

Sørensen JB., Skovsgaard T., Bork E., Damstrup L. and Ingeberg S.

Cancer, 2008, 112, 1600-6

A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

Holländer C., Baeksgaard L., Sorensen M., Albertsson P., Damstrup L., Lassen U.

Anticancer Res. 2012 Sep;32(9):4019-23

Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer

Dizon DS., Damstrup L., Finkler NJ., Lassen U., Celano P., Glasspool R., Crowley E., Lichenstein HS., Knoblach P., Penson RT.

Int J Gynecol Cancer. 2012 Jul;22(6):979-86

Clinical development of new drug-radiotherapy combinations

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR.

NCRI CTRad Academia-Pharma Joint Working Group. Nat Rev Clin Oncol. 2016 Oct;13(10):627-42

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Florian Clatot, Frederic Rolland, Julie Villa, Nicolas Magne, Olgun Elicin, Elisabet Gherga, France Nguyen, Cédrik Lafond, Guillaume Bera, Valentin Calugaru, Lionnel Geoffrois, Bruno Chauffert, Lars Damstrup, Philippa Crompton, Abdallah Ennaji, Kathrin Gollmer, Heidi Nauwelaerts, Jean Bourhis.

European Journal of Cancer, Oxford England 1990.

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS.

Br J Cancer. 2018 Nov 14. doi: 10.1038/s41416-018-0322-4

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Mark T. J. van Bussel, Ahmad Awada, Maja J. A. de Jonge, Morten Mau-Sørensen, Dorte Nielsen, Patrick Schöffski, Henk M. W. Verheul, Barbara Sarholz, Karin Berghoff, Samer El Bawab, Mirjam Kuipers, Lars Damstrup, Ivan Diaz-Padilla & Jan H. M. Schellens.

Br J Cancer. Volume 124, pages 728–735 (2021)

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Yungan Tao, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Florian Clatot, Frederic Rolland, Julie Villa, Nicolas Magne, Olgun Elicin, Elisabeta Gherga, France Nguyen, Cédrik Lafond, Guillaume Bera, Valentin Calugaru, Lionnel Geoffrois, Bruno Chauffert, Lars Damstrup, Philippa Crompton, Abdallah Ennaji, Kathrin Gollmer, Heidi Nauwelaerts, Jean Bourhis.

European Journal of Cancer (in Press)

N/A